Abstract
Background: Neoadjuvant therapy is increasingly being utilized in pancreatic cancer (PDAC) patients. The benefits of minimally invasive pancreaticoduodenectomy (MIPD) over open pancreaticoduodenectomy (OPD) are controversial, and perioperative outcomes of MIPD after neoadjuvant therapy has not been studied.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: HPB : the official journal of the International Hepato Pancreato Biliary Association
Paper Title
Journal
Date
